Labcorp upholds 2026–29 growth view after CMS lab plan
Labcorp reaffirms its 2026–2029 non-GAAP growth and margin outlook while reviewing CMS’s preliminary PAMA-related lab fee cuts for 2027–2029.
Rhea-AI Filing Summary
Labcorp Holdings Inc. (LH) reports that the Centers for Medicare & Medicaid Services released preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under the Protecting Access to Medicare Act, which the company believes rely on unrepresentative market data and would impose steep annual reimbursement cuts.
Labcorp states it had already factored continued PAMA-related reimbursement pressure into its 2026–2029 long-term outlook announced on September 10, 2026 and is reaffirming that outlook: compound annual revenue growth of 5%–8%, adjusted operating margin expansion of 75–150 basis points by the end of 2029, compound annual adjusted EPS growth of 8.5%–11.5%, and compound annual free cash flow growth in line with adjusted earnings growth.
The company supports the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act, is continuing to evaluate the CMS payment rates, and expects to provide additional information on their impact when issuing 2027 financial guidance in February 2027. The growth metrics discussed are non-GAAP measures, which Labcorp presents as supplements to GAAP results.
Positive
- Labcorp reaffirms its 2026–2029 long-term outlook, targeting 5%–8% compound annual revenue growth despite anticipated PAMA-related reimbursement pressure.
- The company projects adjusted operating margin expansion of 75–150 basis points by the end of 2029, along with compound annual adjusted EPS growth of 8.5%–11.5% and free cash flow growth in line with adjusted earnings.
Negative
- Preliminary CMS Clinical Laboratory Fee Schedule rates for 2027–2029 are described as imposing steep annual payment cuts, which Labcorp believes threaten patient access to laboratory services and add reimbursement risk.
- The company highlights ongoing PAMA-related reimbursement pressure as a factor already incorporated into its long-term outlook, underscoring continued regulatory pricing headwinds.
8-K Event Classification
Item 7.01 — Regulation FD Disclosure
1 item
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Key Figures
Compound annual revenue growth outlook: 5%–8%
Adjusted operating margin expansion: 75–150 basis points
Compound annual adjusted EPS growth: 8.5%–11.5%
+3 more
6 metrics
Compound annual revenue growth outlook
5%–8%
Reaffirmed 2026–2029 long-term outlook announced September 10, 2026
Adjusted operating margin expansion
75–150 basis points
Targeted increase by the end of 2029 in long-term outlook
Compound annual adjusted EPS growth
8.5%–11.5%
Reaffirmed 2026–2029 long-term outlook using non-GAAP adjusted EPS
Free cash flow growth outlook
In line with adjusted earnings growth
Compound annual free cash flow growth over 2026–2029
CMS CLFS rate period
2027–2029
Preliminary Clinical Laboratory Fee Schedule payment rates under PAMA
Date of earliest event reported
September 22, 2026
Earliest event date stated in the report
Key Terms
Clinical Laboratory Fee Schedule, Protecting Access to Medicare Act, Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act, free cash flow, +2 more
6 terms
Clinical Laboratory Fee Schedule regulatory
"CMS released preliminary Clinical Laboratory Fee Schedule payment rates"
A clinical laboratory fee schedule is a set list of prices that a payer—such as a government program or insurance company—will reimburse for specific lab tests and services. Think of it as a menu of allowed payments that determines how much labs can charge and get paid; changes to those prices directly affect a lab’s revenue, profit margins and investment prospects because lower rates squeeze earnings while higher rates improve cash flow.
Protecting Access to Medicare Act regulatory
"payment rates applicable from 2027 through 2029 pursuant to the Protecting Access to Medicare Act"
Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act regulatory
"supports the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services"
free cash flow financial
"Compound annual free cash flow growth in line with adjusted earnings growth"
Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.
non-GAAP financial measures financial
"provided in this adjusted financial information that has not been prepared in accordance with GAAP"
Non-GAAP financial measures are numbers companies use to show their financial performance that exclude certain expenses or income. They help investors see how the company might perform without one-time costs or other unusual items, giving a different perspective from official reports. However, since they can be adjusted, they don’t always tell the full story and should be looked at alongside standard financial figures.
forward-looking statements regulatory
"contains forward-looking statements, including, but not limited to, statements with respect to the long-term financial outlook"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What CMS action is Labcorp (LH) disclosing in this 8-K?
Labcorp discloses that on September 21, 2026, CMS released preliminary Clinical Laboratory Fee Schedule payment rates for 2027–2029 under PAMA. Labcorp believes these rates are based on data that do not fully reflect the broader commercial laboratory market and would impose steep annual payment cuts.
How does Labcorp (LH) view the impact of the preliminary CMS lab fee rates?
Labcorp believes the preliminary CMS payment rates would impose steep annual payment cuts and are based on data not fully representative of the broader commercial laboratory market, which it says would threaten patient access to laboratory services. The company is continuing to evaluate the rates’ impact.
What long-term revenue growth outlook does Labcorp (LH) reaffirm for 2026–2029?
Labcorp reaffirms a 2026–2029 long-term outlook that includes compound annual revenue growth of 5%–8%. This outlook was first announced at its Investor Day on September 10, 2026 and already contemplated continued PAMA-related reimbursement pressure.
What margin and EPS growth targets does Labcorp (LH) reaffirm?
Labcorp reaffirms adjusted operating margin expansion of 75–150 basis points by the end of 2029 and compound annual adjusted EPS growth of 8.5%–11.5% over 2026–2029. These are non-GAAP measures that the company presents as supplements to GAAP results.
What is Labcorp’s (LH) outlook for free cash flow over 2026–2029?
Labcorp expects compound annual free cash flow growth over 2026–2029 to be in line with adjusted earnings growth. Free cash flow is presented as a non-GAAP measure, and reconciliations are not provided on a forward-looking basis.
When will Labcorp (LH) update investors on the CMS rate impact to 2027 guidance?
Labcorp states it is continuing to evaluate the CMS payment rates and expects to provide additional information on their impact when its 2027 financial guidance is announced in February 2027.
What legislative change does Labcorp (LH) support regarding PAMA?
Labcorp states it supports the bipartisan Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act, describing it as a bipartisan solution designed to ensure the U.S. has a sustainable and innovative laboratory system amid PAMA-related reimbursement pressures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
